Sudarshan Pharma Industries Reports Strong Performance; Q3 Net Profit Climbs 56%

MUMBAI– Sudarshan Pharma Industries Limited today announced its unaudited financial results for the quarter and nine months ended December 31, 2025.

The company reported a significant increase in its standalone net profit for the quarter, rising 56% year-on-year to ₹430.54 lakhs, compared to ₹275.82 lakhs in the same period last year.

Quarterly Financial Highlights (Standalone)

Revenue from Operations: Stood at ₹15,837.13 lakhs for Q3 FY26, a growth of 37% over ₹11,558.23 lakhs in Q3 FY25.
Net Profit: Jumped to ₹430.54 lakhs from ₹275.82 lakhs in the previous year’s corresponding quarter.
Total Income: Reached ₹16,006.09 lakhs for the quarter ended December 31, 2025.
Earnings Per Share (EPS): Basic and diluted EPS for the quarter was ₹0.18, up from ₹0.11 in Q3 FY25.

Nine-Month Performance

For the nine-month period ending December 31, 2025, the company’s standalone revenue from operations surged to ₹46,768.87 lakhs, compared to ₹34,092.53 lakhs in the same period of the previous fiscal year. Net profit for the nine months grew substantially to ₹1,243.89 lakhs from ₹699.47 lakhs.

Strategic Developments and Global Expansion

Sudarshan Pharma continues its aggressive growth strategy with several key developments during the quarter:

New Global Subsidiary: On December 17, 2025, the company formed “SUDARSHAN PHARMA POLAND LIMITED LIABILITY COMPANY” as a wholly-owned subsidiary. This new entity will focus on manufacturing basic chemicals, fertilizers, and plastics in Poland.
Fundraising through FCCB: The company has received in-principle approval from BSE and a Loan Registration Number from the RBI to raise up to ₹1,500 Crores (approx. USD 35 Million) via Foreign Currency Convertible Bonds (FCCB).
Strategic Acquisition: The company is progressing with its ₹25.50 crore acquisition of an Active Pharmaceutical Ingredients (API) manufacturing facility in Telangana from Srigen Lifesciences Private Limited.
Litigation Success: The company continues to receive payments following a Dubai Court award in its favour against Regans International DMCC. As of December 31, 2025, it has recovered ₹3.69 crores of the approximately ₹91.88 crore awarded amount.

Business Outlook

The company, which specialises in API manufacturing and speciality chemicals, transitioned to Indian Accounting Standards (Ind AS) voluntarily starting April 1, 2025. Management remains focused on expanding its manufacturing footprint and diversifying its international presence through its new subsidiaries in Singapore, Dubai, and now Poland.